• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International wound journal. >Evaluation of clinical and financial outcomes of a new no-sting barrier film and barrier cream in a large UK primary care organisation
【24h】

Evaluation of clinical and financial outcomes of a new no-sting barrier film and barrier cream in a large UK primary care organisation

机译：在一家大型英国基层医疗机构中评估新的无刺激性隔离膜和隔离霜的临床和财务结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The study involves 95 subjects within a UK Primary Care Organisation and was undertaken in two arms. The objective was to determine the clinical outcomes and clinical acceptability of a newly available range of no-sting barrier film and no-sting barrier cream products offering significant financial benefits. The importance of undertaking this study is underpinned by evidence in the literature relating to the use of no-sting barrier preparations within clinical practice. The first part of the study (arm 1) involved extensive evaluation of either the film or cream barrier in 36 patients and was compared to existing standardised barrier protection care within the organisation. The results indicated that the new product range met all the criteria for formulary inclusion and following this the barrier range was further evaluated in arm 2, 33 patients with barrier cream and 26 patients with barrier film. The entire study was conducted over a 3-month period with patient treatment lasting a minimum of 2 days to a maximum 4-week period adhering to the agreed evaluation protocol as approved by clinical governance. In arm 1 (n = 36), the clinical expectation of the product was met in 32 cases relating to ease of use, conformability, no-sting, quick drying, ease of absorption, compatibility with devices, frequency of application, prevention and management including visual skin improvement resulting in a recommendation for formulary listing in 31 of 36 cases. In arm 2 (n = 59), barrier film and barrier cream performance was consistently rated same as, better than or much better than the existing barrier used. A formulary listing recommendation was made in 51 of 59 cases.
机译：该研究涉及英国初级卫生保健组织内的95个受试者，并分两部分进行。目的是确定具有显着财务效益的一系列新的无刺痛隔离膜和无刺痛隔离霜产品的临床结果和临床可接受性。开展这项研究的重要性得到了有关在临床实践中使用无毒屏障制剂的文献证据的支持。该研究的第一部分（第1部分）涉及对36位患者的薄膜或乳膏屏障的广泛评估，并将其与组织内现有的标准化屏障保护护理进行了比较。结果表明，该新产品系列满足所有配方纳入标准，并在此之后进一步评估了第2组，33例屏障霜患者和26例屏障膜患者的屏障范围。整个研究历时3个月，患者治疗持续至少2天，最长持续4周，并遵守临床治理批准的评估协议。在第1组（n = 36）中，在32例患者中满足了产品的临床期望，涉及易用性，顺应性，不发臭，速干，易吸收，与设备兼容，应用频率，预防和管理包括视觉皮肤改善，因此建议在36例病例中有31例列入处方清单。在第2臂（n = 59）中，隔离膜和隔离霜的性能始终被评为与使用的现有隔离相同，更好或更好。在59个案例中，有51个列出了处方列表。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号